|Day Low/High||55.25 / 55.26|
|52 Wk Low/High||7.26 / 59.25|
Approximately 79 percent of outstanding Gentium ordinary shares and American Depositary Shares tendered
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of holders of Gentium S.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, announces that a class action lawsuit against the Board of Directors of Gentium S.
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Gentium S.
Transaction would add a significant growth product in the European Union and Rest of World markets, Defitelioa¿¢ (defibrotide), a treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Trade-Ideas LLC identified Gentium SpA (GENT) as a new lifetime high candidate
Conference Call and Webcast on Thursday October 31, 2013
James Dennin, Kapitall: Can Italian stocks rise above the antics of Silvio Berlusconi? This puts ourÂ own governmental woes inÂ perspective. The [...]
These stocks are rising on unusual volume into breakout territory.
Conference Call and Webcast on Tuesday August 13, 2013